Barclays’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Barclays’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-224	Closed	-$1.81M	–	7255
2015 Q1	$1.81M	Buy	+224	New	+$1.96M	﹤0.01%	2412

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Barclays's EIGR Position: Q2 2023 in Review

Barclays sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 709 shares — an estimated $19.1K sold.

Barclays first reported a position in EIGR in Q2 2014 and held it in 26 quarters. The position peaked at $4.19M in Q1 2022. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

Barclays reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Barclays sold 709 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $19.1K.
Barclays first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 26 quarters.
Barclays's Eiger BioPharmaceuticals, Inc. position peaked at $4.19M in Q1 2022.
66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.